📊 GBCS Key Takeaways
Is GBCS a Good Investment? Thesis Analysis
Selectis Health exhibits severe financial distress with negative stockholders' equity of -$5.7M, indicating the company is technically insolvent. The company is unprofitable with negative operating and net margins, minimal liquidity (0.19x current ratio), and insufficient cash reserves ($417K) relative to debt obligations ($18.5M long-term debt). While operating cash flow is positive at $1.2M, this cannot offset the fundamental deterioration in financial position and lack of clear path to profitability.
Why Buy GBCS? Key Strengths
- Positive operating cash flow of $1.2M demonstrates some cash generation capability
- Revenue growth of 7.4% YoY shows modest top-line expansion
- Positive free cash flow of $851K provides limited financial flexibility
GBCS Investment Risks to Consider
- Negative stockholders' equity of -$5.7M indicates technical insolvency and bankruptcy risk
- Critically low liquidity with current ratio of 0.19x creates immediate solvency concerns
- Persistent operating losses (-$1.2M) and negative net margins (-0.7%) with no clear profitability trajectory
- High leverage with $18.5M long-term debt versus only $417K cash, creating debt service vulnerability
- Negative interest coverage ratio (-0.5x) indicates inability to service debt from operations
Key Metrics to Watch
- Stockholders' equity trend - critical to monitor if returning to positive territory
- Operating margin improvement - must achieve profitability to reverse distress trajectory
- Liquidity position and cash burn rate - essential given minimal cash reserves
- Debt refinancing or restructuring activities - bankruptcy risk mitigation efforts
GBCS Financial Metrics
💡 AI Analyst Insight
The relatively thin 2.7% FCF margin may limit capital allocation flexibility. The current ratio below 1.0x warrants monitoring of short-term liquidity.
GBCS Profitability Ratios
GBCS vs Default Sector
How SELECTIS HEALTH, INC. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GBCS Overvalued or Undervalued?
Based on fundamental analysis, SELECTIS HEALTH, INC. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GBCS Balance Sheet & Liquidity
GBCS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: SELECTIS HEALTH, INC.'s revenue has grown significantly by 89% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.31 indicates the company is currently unprofitable.
GBCS Growth Metrics (YoY)
GBCS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $10.0M | -$211.6K | $-0.08 |
| Q2 2025 | $9.6M | -$240.4K | $-0.08 |
| Q1 2025 | $9.5M | -$656.0K | $-0.22 |
| Q3 2024 | $9.0M | -$337.9K | $-0.11 |
| Q2 2024 | $8.9M | -$240.4K | $-0.08 |
| Q1 2024 | $9.5M | -$1.0M | $-0.34 |
| Q3 2023 | $9.0M | $37.1K | $-0.07 |
| Q2 2023 | $8.9M | $228.7K | $0.34 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GBCS Capital Allocation
GBCS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for SELECTIS HEALTH, INC. (CIK: 0000727346)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GBCS
What is the AI rating for GBCS?
SELECTIS HEALTH, INC. (GBCS) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are GBCS's key strengths?
Claude: Positive operating cash flow of $1.2M demonstrates some cash generation capability. Revenue growth of 7.4% YoY shows modest top-line expansion.
What are the risks of investing in GBCS?
Claude: Negative stockholders' equity of -$5.7M indicates technical insolvency and bankruptcy risk. Critically low liquidity with current ratio of 0.19x creates immediate solvency concerns.
What is GBCS's revenue and growth?
SELECTIS HEALTH, INC. reported revenue of $31.8M.
Does GBCS pay dividends?
SELECTIS HEALTH, INC. pays dividends, with $0.4M distributed to shareholders in the trailing twelve months.
Where can I find GBCS SEC filings?
Official SEC filings for SELECTIS HEALTH, INC. (CIK: 0000727346) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GBCS's EPS?
SELECTIS HEALTH, INC. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GBCS a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, SELECTIS HEALTH, INC. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GBCS stock overvalued or undervalued?
Valuation metrics for GBCS: ROE of N/A (sector avg: 15%), net margin of -0.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GBCS stock in 2026?
Our dual AI analysis gives SELECTIS HEALTH, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GBCS's free cash flow?
SELECTIS HEALTH, INC.'s operating cash flow is $1.2M, with capital expenditures of $387.0K. FCF margin is 2.7%.
How does GBCS compare to other Default stocks?
Vs Default sector averages: Net margin -0.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.19 (avg: 1.8).